格隆汇8月26日丨银诺医药-B(02591.HK)发布公告，2026年8月26日起至公司下一届股东周年大会日期止期间，其拟根据股东于2026年6月29日举行的股东周年大会上通过的特别决议案行使其于购回授权下的权力，于联交所主板以场内交易方式购回H股，拟定总金额约为5000万港元(“拟定H股购回”)。 公告表示，在目前情况下进行拟定H股购回，显示公司对其业务展望及前景充满信心，并将最终为公司带来裨益及为股东创造价值。董事会将动用可合法作此用途的公司内部资源资金进行拟定H股购回。董事会认为，公司现有财务资源足以支持拟定H股购回，同时维持稳健的财务状况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.